CSL Limited (ASX:CSL – Get Free Report) insider Paul McKenzie acquired 8,275 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was purchased at an average price of A$306.03 ($208.18) per share, for a total transaction of A$2,532,398.25 ($1,722,719.90).
CSL Stock Performance
The company has a quick ratio of 1.68, a current ratio of 2.17 and a debt-to-equity ratio of 62.80.
CSL Increases Dividend
The firm also recently disclosed a Final dividend, which will be paid on Tuesday, October 1st. Investors of record on Tuesday, October 1st will be paid a $2.203 dividend. This represents a yield of 0.73%. This is a positive change from CSL’s previous Final dividend of $1.99. The ex-dividend date of this dividend is Sunday, September 8th. CSL’s payout ratio is currently 49.69%.
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Recommended Stories
- Five stocks we like better than CSL
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- How to Evaluate a Stock Before Buying
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- Options Trading – Understanding Strike Price
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
